| NCT ID | NCT07570264 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nunaps Inc |
| Condition | Aphasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 116 participants |
| Start Date | 2026-04-16 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 116 participants in total. It began in 2026-04-16 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the efficacy of digital language rehabilitation using LEXURE for the treatment of post-stroke aphasia. Half of participants will receive structured language training using the LEXURE application, while the other half will receive workbook-based language training as an active comparator.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with hemorrhagic or ischemic stroke 2. At least 3 months have elapsed since stroke onset 3. History of aphasia resulting from stroke 4. Aphasia Quotient (AQ) score between 26 and 90 (inclusive) on the Korean version of the Western Aphasia Battery (K-WAB) or the Paradise Korean version of the Western Aphasia Battery-Revised (PK-WAB-R) 5. Adults aged 19 years or older 6. Native Korean speakers 7. Able to use the investigational device or perform workbook-based training without difficulty 8. Willing to participate voluntarily and provide written informed consent Exclusion Criteria: 1. Diagnosed with language impairment due to causes other than stroke (e.g., traumatic brain injury, brain tumor, or neurodegenerative disease) 2. History of language impairment due to developmental disorders 3. Currently receiving speech-language therapy or participating in another clinical trial related to language function 4. Currently receiving medication for severe psychiatric disorders (e.g., bipolar disorder, major depressive disorder, schizophrenia, alcohol dependence, or substance abuse) 5. Illiterate individuals 6. Individuals deemed unsuitable for participation in this study by the investigator 7. Severe cognitive impairment that would interfere with understanding or performing the study interventions
Contact & Investigator
Sung Il Sohn, MD, PhD
STUDY CHAIR
Keimyung University Dongsan Medical Center
Frequently Asked Questions
Who can join the NCT07570264 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07570264 currently recruiting?
Yes, NCT07570264 is actively recruiting participants. Contact the research team at skjung@nunaps.com for enrollment information.
Where is the NCT07570264 trial being conducted?
This trial is being conducted at Ansan, South Korea, Busan, South Korea, Chuncheon, South Korea, Daegu, South Korea and 8 additional locations.
Who is sponsoring the NCT07570264 clinical trial?
NCT07570264 is sponsored by Nunaps Inc. The principal investigator is Sung Il Sohn, MD, PhD at Keimyung University Dongsan Medical Center. The trial plans to enroll 116 participants.